Statements

Find out what Breast Cancer Care is saying about the latest drug treatments, research papers and health policy issues.

If you’re working on a story and need an expert quote, call us on 0345 092 0807 (out of hours 07702 901 334).

Responding to the decision from NICE that palbociclib (Ibrance) and ribociclib (Kisqali)* have been approved for use on the NHS in England, Samia al...

Responding to Louise Wilson (played by Pooky Quesnel) in The A Word being diagnosed with breast cancer, Samia al Qadhi, Chief Executive of Breast Cancer...

Thursday 9 November 2017: Responding to the announcement that NHS England and Roche have reached a commercial agreement in principle on the use of...

Responding to new analysis by Macmillan Cancer Support suggesting thousands of people with secondary cancers are surviving for several years after...

Responding to findings from the OncoArray Consortium project on gene variants which may heighten breast cancer risk, Grete Brauten-Smith, Clinical Nurse...

Responding to the England Cancer Strategy 2016/2017 Progress Report, Gunes Kalkan, Head of Policy and Campaigns at Breast Cancer Care, says:...

Responding to NICE’s draft decision not to recommend fulvestrant (Faslodex) for use by the NHS in England for the treatment of ER positive...

Responding to the news that immune cell ‘hotspots’ could help identify women at high risk of relapsing breast cancer, Jane Murphy, Clinical...

Responding to a new study, published in the journal Clinical Chemistry, that suggests the prospect of further personalisation of treatment for...

Responding to the Cancer Patient Experience Survey, released today, David Crosby, Director of Services and Engagement at Breast Cancer Care, says:...

Sign up for our newsletter